HALOZYME THERAPEUTICS, INC.
HALO—
HALOZYME THERAPEUTICS, INC.HALO$0.00
+$0.00(+NaN%)Past Year
Jun 25Sep 25Dec 25Mar 26Jun 26
Key statistics
Market cap
—
P/E ratio
—
EPS (diluted)
$2.56
Dividend yield
0.00%
Dividend / share
$0.00
Revenue
$1.40B
Net income
$316.89M
Net margin
22.7%
Gross margin
0.4%
Dividends & financials
HALOZYME THERAPEUTICS, INC. (HALO) reported revenue of $1.40B and net income of $316.89M, or $2.56 per diluted share. It does not currently pay a dividend. Financial figures are sourced from the company’s latest public filings; the price chart updates live, 24/7, even when the underlying market is closed.